CDKN2A and acute lymphoblastic leukemia: This may in part be due to a low number of Ph+ ALL patients in these studies, and a targeted evaluation of IKZF1, PAX5, and CDKN2A/B susceptibility alleles specifically in Ph+ ALL patients may be warranted.